AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026Initial data ...

Acurastem received a grant to develop ALS therapies targeting SYF2, a regulator of TDP-43, in collaboration with academic research teams.

A mutation in the TDP-43 protein reduces the viability of motor neurons without triggering protein clumps, researchers found.

BOSTON--(BUSINESS WIRE)--SOLA Biosciences, a pioneer in innovative chaperone technology, will present its encouraging preclinical proof-of-concept data for SOL-257, a targeted gene therapy for ...

BOSTON--(BUSINESS WIRE)--As a pioneer in innovative chaperone technology, SOLA Biosciences Inc. will present its compelling preclinical proof-of-concept data for SOL-257, a targeted gene therapy for ...

In amyotrophic lateral sclerosis and frontotemporal dementia, loss of the RNA-binding protein TDP-43 from the nucleus creates a surge of mis-spliced mRNAs in neurons. So far, only one of these errant ...

In TDP-43 proteinopathies, such as frontotemporal dementia, amyotrophic lateral sclerosis, and limbic predominant age-related TDP-43 encephalopathy, the notorious RNA binding protein abandons its post ...

First-in-class condensate-modulating small molecule Development Candidate targeting pathogenic TDP-43 condensates. Restores global TDP-43 splicing function in disease-relevant systems. Demonstrates in ...

TDP-43 CYTOPE® preclinical data demonstrates the potential of Prothena’s CYTOPE technology as a novel modality for delivering large molecules into cells, enabling precise targeting of intracellular ...

The TDP-43 RNA-binding protein is found in abnormal cytoplasmic inclusions in affected motor neurons in almost all ALS cases, and mutations in the TDP-43 gene (TARDBP) cause a rare form of familial ...